Jackie Orfanos, MD
Internal Medicine · Plainview, NYNPI 1548250715
Payments from drug & device makers
Across 337 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$947
- Novo Nordisk$821
- AstraZeneca$687
- Inspire Medical Systems, Inc.$477
- Kowa Pharmaceuticals America, Inc.$403
- plus $4K from 34 others
What the payments were for
- Food & beverage$8,416100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,379 |
| Amgen | 20 | $947 |
| Novo Nordisk | 30 | $821 |
| AstraZeneca | 21 | $687 |
| Inspire Medical Systems, Inc. | 8 | $477 |
| Kowa Pharmaceuticals America, Inc. | 23 | $403 |
| Lilly USA, LLC | 11 | $343 |
| Novartis | 6 | $297 |
| GSK | 12 | $245 |
| Esperion Therapeutics, Inc. | 12 | $228 |
| Amarin Pharma, Inc. | 12 | $227 |
| Pfizer | 12 | $211 |
| Sumitomo Pharma America, Inc. | 3 | $200 |
| Johnson & Johnson | 4 | $173 |
| Merck | 8 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $161 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Eisai Inc. | 5 | $123 |
| Ardelyx, Inc. | 5 | $123 |
| Tolmar, Inc. | 6 | $117 |
| IBSA Pharma Inc. | 5 | $91 |
| Bausch Health US, LLC | 5 | $91 |
| Corium, LLC | 5 | $90 |
| Corcept Therapeutics | 3 | $85 |
| Sanofi Pasteur Inc. | 4 | $75 |
| Antares Pharma, Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Abbott | 3 | $64 |
| Exact Sciences | 2 | $46 |
| Currax Pharmaceuticals LLC | 3 | $46 |
| Astellas Pharma US Inc | 2 | $37 |
| Acerus Pharmaceuticals Corporation | 2 | $36 |
| Dexcom, Inc. | 1 | $29 |
| Biogen | 1 | $24 |
| Phadia US Inc. | 1 | $21 |
| Medtronic | 1 | $20 |
| Shield Therapeutics Inc | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,416 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $49,094 |
| TrulicityDulaglutide | 27 | $31,188 |
| EliquisApixaban | 27 | $30,874 |
| MounjaroTirzepatide | 26 | $29,038 |
| ProliaDenosumab | 13 | $22,034 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $19,262 |
| VascepaIcosapent Ethyl | 16 | $9,129 |
| SynthroidLevothyroxine Sodium | 77 | $8,464 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,267 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,093 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $4,514 |
| Bupropion XlBupropion Hcl | 28 | $3,881 |
| Valsartan | 118 | $2,555 |
| Atorvastatin Calcium | 147 | $2,106 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $343 | $60,22653 claims |
| Novo NordiskOzempic | $821 | $49,09448 claims |
| PfizerEliquis | $211 | $30,87427 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $245 | $25,35535 claims |
| AmgenProlia | $947 | $22,03413 claims |
| AbbVieSynthroid | $1,379 | $8,46477 claims |
| AstraZenecaBreztri Aerosphere | $687 | $8,26714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Plainview
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.